Sign In
Buy JAGX
$2.92
-0.300 (-9.32%)
At Close: Jun 03, 2026
Jaguar Health to Hold Investor Webcast Thursday, August 14 at 8:30 AM Eastern Regarding Q2 2025 Financials & Corporate Updates
09:00am, Tuesday, 12'th Aug 2025
Click here to register Company plans to file its Earnings Report on August 14, 2025 on Form 10-Q for the quarter ended June 30, 2025 Jaguar CEO Lisa Conte presenting August 20 at Emerging Growth Confe
Enrollment Initiated in Jaguar Health Study of its FDA Conditionally Approved Canalevia-CA1 Prescription Drug for Dogs
08:30am, Thursday, 10'th Jul 2025
Company strategy: In discussions with multiple potential animal health company partners to collaborate to bring Canalevia®, conditionally approved for CID, to regulatory approval and commercializatio
Coca Access and Benefit Sharing Agreement Authorized by Peru's National Institute of Agrarian Innovation (INIA) Supports Research Efforts of Jaguar Health and Filament Health Joint Venture, Magdalena Biosciences, into Potential Mental Health and CNS Indications of Coca
09:00am, Tuesday, 08'th Jul 2025
Magdalena is focused on developing novel, natural prescription medicines derived from plants for mental health indications SAN FRANCISCO, CA / ACCESS Newswire / July 8, 2025 / Jaguar Health, Inc. (NAS
As recently announced , initial proof-of-concept results from this ongoing investigator-initiated trial (IIT) show crofelemer reduced the required total parenteral nutrition in the first participating
Jaguar Health Board of Directors Authorizes Company to Include Cryptocurrency as a Treasury Reserve Asset
09:00am, Thursday, 26'th Jun 2025
Strategic decision positions Jaguar to diversify treasury holdings with a long-term digital store of value SAN FRANCISCO, CA / ACCESS Newswire / June 26, 2025 / Jaguar Health, Inc. ( NASDAQ:JAGX ) ("J
Jaguar Health to Pursue Approval of Canalevia in European Union for Treatment of General Diarrhea in Dogs
09:00am, Wednesday, 25'th Jun 2025
Canalevia® (crofelemer delayed-release tablets), under the name Canalevia-CA1, is conditionally approved by the FDA for treatment of chemotherapy-induced diarrhea in dogs Jaguar is exploring the poss
Company's CEO, board members, other C-suite members, and institutional and accredited investors are participants in the extension of the bridge financing SAN FRANCISCO, CA / ACCESS Newswire / June 24,
Jaguar Health Provides Updates on Orphan Disease Intestinal Failure Development Program for Crofelemer
09:00am, Monday, 23'rd Jun 2025
Enrollment in company's first-of-its-kind placebo-controlled Phase 2 study to evaluate the efficacy of crofelemer for microvillus inclusion disease (MVID) in pediatric patients has reached approximate
Jaguar Health Presenting June 18 at Emerging Growth Conference to Provide Updates on Near-Term Catalysts
09:00am, Tuesday, 17'th Jun 2025
Click here to register SAN FRANCISCO, CA / ACCESS Newswire / June 17, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, the company's founder, president and CEO, will present v
First Study Site Established for Jaguar Health Study of its FDA Conditionally Approved Canalevia-CA1 Prescription Drug for Dogs
10:00am, Wednesday, 11'th Jun 2025
Two parallel goals for Canalevia-CA1 (crofelemer delayed-release tablets): To obtain full approval of the drug for treatment of chemotherapy-induced diarrhea (CID) and to expand the indication of crof
REMINDER: Jaguar Health to Conduct Fireside Chat 9AM ET June 10 as Part of Lytham Partners' Spring 2025 Spotlight Series
04:15pm, Monday, 09'th Jun 2025
Click here to register Discussion will focus on company's May 2025 meeting with the FDA to review the statistically significant responder analysis results for the subgroup of breast cancer patients in
Productive and collaborative discussion on proposed pathway by the company to bring crofelemer to approval for cancer therapy-related diarrhea (CTD) in patients with metastatic breast cancer receiving
Click here to register SAN FRANCISCO, CA / ACCESS Newswire / June 6, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, the company's founder, president and CEO, will participat
Jaguar Health Announces $1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
08:00am, Wednesday, 21'st May 2025
SAN FRANCISCO, CA / ACCESS Newswire / May 21, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or "the Company"), today announced that it has entered into definitive agreements for the purchase and
As announced , initial proof-of-concept (POC) results from distinct ongoing investigator-initiated trial (IIT) in Abu Dhabi show crofelemer reduced total parenteral support in a pediatric MVID patient
